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Neuropathogenic Forms of Huntingtin
and Androgen Receptor Inhibit
Fast Axonal Transport
lengths of 20–25 glutamines to pathological expansions
of40. Neurological symptoms typically appear in mid-
life, although longer polyQ repeats are associated with
earlier onset of symptoms. Aside from the polyQ tracts,
gene products associated with polyQ diseases exhibit
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symptoms and increased susceptibilities of certain neu-
ronal populations in these diseases are poorly under-
stood, although the latter must be determined by the
Summary
protein context in which polyglutamine expansion is pre-
sented to specific neuronal populations (Gusella and
Huntington’s and Kennedy’s disease are autosomal
MacDonald, 2000; Orr, 2001).
dominant neurodegenerative diseases caused by patho- Various mechanisms have been proposed for neu-
genic expansion of polyglutamine tracts. Expansion of ronal degeneration in polyQ diseases (Hughes and
glutamine repeats must in some way confer a gain of Olson, 2001; Rubinsztein, 2002). Altered neuronal en-
pathological function that disrupts an essential cellu- ergy metabolism was reported in HD, but these changes
lar process and leads to loss of affected neurons. As- may be secondary to pathology and do not explain se-
sociation of huntingtin with vesicular structures raised lective neuronal vulnerability. Excitotoxicity was also
the possibility that axonal transport might be altered. proposed to play a role in neuronal loss, but many neu-
Here we show that polypeptides containing expanded ronal populations sensitive to excitotoxicity are not pri-
polyglutamine tracts, but not normal N-terminal hun- mary targets in these diseases. Discovery of intranuclear
tingtin or androgen receptor, directly inhibit both fast inclusions in neurons of HD patients led to suggestions
axonal transport in isolated axoplasm and elongation that these deposits might cause neuronal death. How-
of neuritic processes in intact cells. Effects were ever, studies on animal and cellular models indicate
greater with truncated polypeptides and occurred that formation of nuclear and cytoplasmic inclusions
without detectable morphological aggregates. correlates poorly with neuronal death and may be pro-
tective in some cases (Emamian et al., 2003; Orr, 2001;
Rubinsztein, 2002), leaving open the question of whetherIntroduction
nuclear localization and aggregation are required for
pathogenesis. Regardless, molecular mechanisms byUnderstanding pathogenic mechanisms is essential for
which aggregate formation or altered protein structuresdevising effective treatments for neurodegenerative dis-
associated with polyglutamine expansions compromiseeases. Glutamine repeat expansion diseases include
neuronal function and lead to neuronal death are notHuntington’s disease (HD), Kennedy’s disease or Spino-
apparent. Evidence that critical neuronal pathways arebulbar Muscular Atrophy (SBMA), Dentatorubral-Pallid-
altered is seen in reports that SCA1 phosphorylationoluysian Atrophy, and Spinocerebellar Ataxias (SCA
plays an important role in pathogenesis of SCA1 micetypes 1, 2, 3, 6, and 7) (Fischbeck, 2001; Gusella and
(Chen et al., 2003; Emamian et al., 2003). Regardless,MacDonald, 2000; Zoghbi and Orr, 2000). In each case,
one or more cellular component essential to neuronaldisease results from increases in the number of residues
function must be altered pathologically to trigger neu-in a polyglutamine (polyQ) tract, ranging from normal
ronal degeneration.
Cytoplasmic localization and association with vesicu-
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with normal trafficking of vesicles in fast axonal trans-Dallas, Texas 75390.
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1999), whereas SCA2 is localized exclusively in cyto- movements in axoplasms perfused with polypeptides
containing shorter polyQ tracts (HD548-Q2flag, -Q23flag,plasm (Huynh et al., 2000). Although present in nuclei,
huntingtin is predominantly cytoplasmic where it may and -Q23GFP) were indistinguishable from empty
pcDNA controls. Therefore, only N-terminal huntingtinbe associated with vesicles or cytoskeletal structures
(DiFiglia et al., 1995; Trettel et al., 2000; Trottier et al., polypeptide fragments containing polyQ segments in
the disease-associated range disrupt fast axonal1995; Velier et al., 1998). Huntingtin is also moved in fast
axonal transport (Block-Galarza et al., 1997), consistent transport.
Wild-type, full-length huntingtin is associated with cy-with vesicle association. To determine whether normal
or pathogenic polyQ-containing polypeptides affect toplasmic vesicles (DiFiglia et al., 1995; Sharp et al.,
1995), a subcellular location consistent with effects onvesicle transport in neurons, recombinant N-terminal
huntingtin fragments were perfused into isolated axo- vesicle transport. To see whether recombinant polypep-
tides comprising the huntingtin N-terminal 548 aa withplasm from squid giant axons, and effects on fast axonal
transport were assessed under conditions with no de- various polyQ lengths were comparably localized in axo-
plasm, preparations perfused with HD548-Q23flag ortectable aggregates or nuclei. Only pathogenic forms
inhibited vesicle transport. The effects of huntingtin HD548-Q62flag were immunolabeled with antiFLAG an-
tibodies (Figure 1E). Staining patterns obtained forraised the question of whether inhibition of transport
was a general characteristic of expanded polyglutamine HD548-Q23 and HD548-Q62 were indistinguishable in
multiple images from multiple axoplasms prepared bysegments or unique to truncated huntingtin polypep-
tides. To test whether other proteins with pathological two fixation protocols (formaldehyde, Figure 1E; and
alcohol/acid, not shown) and probed with two differentpolyglutamine expansions inhibited axonal transport, ef-
fects on transport of full-length and truncated androgen anti-FLAG antibodies (M2, Figure 1E; and M5, not
shown). Immunoreactivity appeared as small punctatereceptors with normal or pathogenic length polygluta-
mine tracts were evaluated in isolated axoplasm and structures reminiscent of patterns obtained in isolated
axoplasm with antibodies against kinesin heavy or lighttransport-dependent events in cultured cells.
chains (Brady et al., 1990; Stenoien and Brady, 1997).
Kinesin in these preparations is almost entirely associ-Results
ated with membrane bounded organelles (Tsai et al.,
2000). Given the association of huntingtin with vesicularRecombinant Huntingtin Fragment with PolyQ
structures in vivo (DiFiglia et al., 1995; Sharp et al., 1995),Expansion Inhibits Fast Axonal Transport
these puncta are likely to represent axoplasmic vesicles.in Isolated Axoplasm
No evidence of aggregate formation was seen with ei-To assess effects on transport, polypeptides comprising
ther HD548-Q23flag or -Q62flag N-terminal huntingtinamino acids (aa) 1–548 of human huntingtin (HD548)
polypeptides. This suggests that huntingtin N terminuswith 2, 23, 62, or 100 Qs were expressed by in vitro
is sufficient for localization to vesicular structures andtranslation. Recombinant polypeptides included either
that expansion of polyQ tracts does not interfere withN terminus FLAG or C terminus Green Fluorescent Pro-
localization. Therefore, pathogenic polyQ-containingtein (GFP) epitope tags (Figure 1A). Nonpathogenic
N-terminal huntingtin polypeptides inhibited axonal trans-(HD548-Q2 and -Q23) and pathogenic (HD548-Q62 and
port without any apparent change in distribution pat--Q100) length polypeptides were perfused into axo-
terns.plasm extruded from giant axons of the squid Loligo
pealii (Brady et al., 1985). Final concentration of recom-
binant huntingtin in axoplasm was typically 0.1–0.2 nM. SBMA-Associated Forms of PolyQ Androgen
Receptor Attenuate MorphologicalBy comparison, kinesin concentration in squid axo-
plasm is 0.5 M (Brady et al., 1990; Stenoien and Differentiation of Neuronal Cell Lines
To determine whether inhibition of axonal transport wasBrady, 1997) and tubulin is 50 M (Morris and Lasek,
1984). unique to N-terminal huntingtin fragments with polyQ
expansion or a general characteristic of proteins withWhen control buffers or N-terminal huntingtin poly-
peptides containing 2 or 23 glutamines were perfused polyQ expansion, SH-SY5Y human neuroblastoma cells
were stably transfected with androgen receptor (AR)into axoplasm, fast axonal transport in both anterograde
and retrograde directions continued unchanged for 1 constructs containing wild-type Q20 and pathogenic
(SBMA) Q56 tracts. Untransfected SH-SY5Y cells con-hr (Figure 1B). In contrast, perfusion with huntingtin con-
taining expanded polyQ tracts (Q62 or Q100) reduced tain very low levels of endogenous AR (Grierson et al.,
2001). Position of the AR polyQ stretch is illustrated inmean transport velocities in both anterograde and retro-
grade directions by 50% within 50 min (Figure 1C). Figure 2A. Stably transfected cell lines were selected
for moderate expression levels (see Figures 2B–2D) toSignificant declines in transport rates were evident
within 25–35 min of perfusion. Reduced rates were ac- avoid artifacts associated with overexpression of re-
combinant polypeptides (Szebenyi et al., 2002). Threecompanied by substantial reductions in amounts of vesi-
cle traffic both in the axoplasm interior (Figure 1C) and transfected clones were selected for further character-
ization: wtAR with full-length AR-Q20, 902-13 with fullon isolated microtubules at axoplasmic edges (not
shown). Comparisons of transport rates between axo- length AR-Q56, and 902-6 with both full-length AR-Q56
and a spontaneously generated polyQ AR N-terminalplasms perfused with different N-terminal huntingtin
polypeptides (Figure 1D) show that reductions occurred fragment (Figure 2B). The AR N-terminal fragment re-
acted with antibodies recognizing aa 1–20 of the AR,only with expanded polyQ polypeptides (HD548-
Q62flag, -Q100flag [not shown], and -Q62GFP). Vesicle U402 (Figure 2B) and N20 (Figure 2E), but not with 441
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Figure 1. Pathogenic Forms of Recombinant Huntingtin Inhibit Fast Axonal Transport in Isolated Axoplasm
(A) Expression vectors encoding amino acids 1–548 of human huntingtin (HD548) with 2 and 23 (nonpathogenic) and 62 and 100 (pathogenic)
Qs were constructed and polypeptides synthesized by in vitro translation. Constructs either had a FLAG epitope tag at their N terminus or
Green Fluorescent Protein (GFP) at their C terminus.
(B) Perfusion of 0.1–0.2 nM HD548-Q23flag had no effect on fast axonal transport in either anterograde or retrograde direction over 50 min.
(C) Perfusion of HD548-Q62flag at concentrations comparable to HD548-Q23flag resulted in a time-dependent reduction of 50% over 50
min in the mean velocity of vesicles moving in fast axonal transport, both anterograde and retrograde.
(D) Histograms comparing actions of pathogenic and nonpathogenic polypeptides on fast axonal transport after 25–35 min of observation.
Fast axonal transport in the presence of nonpathogenic polypeptides was indistinguishable from vector controls (pCDNA) or unperfused
axoplasm (data not shown). In contrast, fast axonal transport was significantly reduced (*p  0.001 in a pooled t test) by polypeptides
containing pathogenic numbers of glutamines.
(E) By immunofluorescence, both pathogenic and nonpathogenic HD548 perfused into axoplasm appear as small punctate structures. No
evidence of aggregate formation was seen for either HD548-Q62flag or HD548-Q23flag peptides. Results of staining with M2 antiFLAG antibody
are shown. Scale bar equals 2.0 m.
antibody against aa 299–315 (Figure 2C) or U407 anti- 1E). Recombinant AR was seen by immunofluorescence
in both nucleus and cytoplasm of all three cell linesbody against aa 200–220 (numbering as in wt AR-Q20)
(not shown) on immunoblots. Staining with 1C2, an anti- (Figures 2F–2H), with immunoreactivity concentrated in
nuclei of a subset of cells. Although expression levelsbody that binds to polyQ tracts containing 20 gluta-
mines (Perez et al., 1999; Trottier et al., 1995), confirmed and relative subcellular distributions of AR varied be-
tween cells within the same culture, immunostainingthat the small AR fragment included a polyQ segment
(Figure 2E, middle panel). Cells expressed full-length levels with antibodies against AR N-terminal (Figure 2F,
N20) were consistently higher in 902-6 cells than in wild-wild-type AR at approximately 7 times the level of the
two mutant cell lines (902-6 and 902-13) (Figure 2D). type or 902-13 cells. Staining intensities with antibodies
against AR C-terminal epitopes not present in the frag-Subcellular location of polyQ-AR proteins was exam-
ined by immunoblotting of subcellular fractions (Figure ment were comparable (Figure 2F, 441). Significantly,
there was no evidence of morphologic aggregates in2E) and immunofluorescence of fixed cells (Figures 2F–
2H). Immunoblots of subcellular fractions from each cell either cytoplasm or nucleus in any of the cell lines de-
spite examination of hundreds of cells under the micro-line showed enrichment of small polyQ AR fragment in
soluble cytoplasmic fractions (Figure 2E). Full-length AR scope and in digital images. These observations sug-
gest that the fragment was stable and accumulated in(both wild-type and pathogenic) was enriched in mem-
brane fractions, similar to apparent localization of cells comparably in nuclear and cytoplasmic compart-
ments. Under these culture conditions, no aggregates ofN-terminal huntingtin on vesicles in axoplasm (Figure
Neuron
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Figure 2. A Truncated PolyQ Containing AR N-Fragment Accumulates in AR-Q56 Transfected SH-SY5Y Cell Cytoplasm
(A) Schematic showing domain organization of human AR: sequence locations for carboxyl hormone binding (aa 669–917; dark gray), DNA
binding (aa 557–623; white), and amino-terminal transactivation domains (aa 1–529; light gray) are indicated. A polyglutamine tract near the
N terminus (black box, starting at aa 58) contains Q20 in wtAR, and Q56 in 902-6 and 902-13 stably transfected clones of SH-SY5Y cells.
(B) Immunoblot with U402 antibody (against AR aa 1–20) of cell lysates of wtAR (1), 902-6 (2), or 902-13 (3). Wild-type AR-Q20 is expressed
at higher levels and, as expected, runs at a lower MW (110 kDa, arrow) than AR-Q56 in 902-6 and 902-13 clonal lines. In 902-6 cells, an
additional band (*) is seen at MW 25 KD.
(C) Immunoblot of cell lysates with 441 antibody (AR aa 299–315, Santa Cruz) shows reactivity with full-length AR but not with the polyQ-
containing AR N-terminal fragment in 902-6 cells. Symbols are as in (B).
(D) Quantitation of full-length AR in the three cell lines. Cultures were done in triplicate for each cell line and gels loaded at constant total
protein. Bars show relative band intensities normalized to loading controls. The y axis is shown in arbitrary units. Standard deviations are
indicated. AR is undetectable in nontransfected cells. Cells transfected with wtAR expressed 7 times as much AR as either cell line expressing
mutant AR. Therefore, effects seen with mutant AR were due to the presence of mutations rather than expression artifacts.
(E) Immunoblots of microsomal (1–3) and cytosolic (4–6) fractions of wtAR (1 and 4), 902-6 (2 and 5), and 902-13 (3 and 6) cells with N20
antibody confirm that polyQ-AR is present in compartments outside the nucleus. Symbols are as in (B). Staining with 1C2 (Chemicon) antibody
that reacts with polyQ tracts containing 20 Qs demonstrates presence of a polyQ stretch in both full-length AR and cytoplasmic N-terminal
fragments. The membrane protein GAP-43 (Boehringer Mannheim) is not in cytosolic fractions.
(F) Cultures of wtAR, 902-6, and 902-13 were triple stained with N20 (AR aa 1–20, Santa Cruz) and 441 Abs and a nuclear-specific Hoechst
(H) dye. Staining patterns and intensities are similar in each of the three cell lines with 441, whereas staining intensity with N20 in the 902-6
cells is much higher due to reaction with N-terminal fragment. In every cell line and with each anti-AR antibody, immunoreactivity was observed
throughout the nucleus and cytoplasm.
(G) Higher magnification images of 902-6 cells double immunostained with N20 and DM1A (anti -tubulin) show that polyQ-AR is found in
both nuclear and cytoplasmic compartments.
(H) Double staining with N20 and 1C2 shows that epitopes recognized by these antibodies colocalize. Note absence of either cytoplasmic or
nuclear aggregates with these antibodies.
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polyQ-expanded polypeptides were apparent in either were immunostained. Staining was punctate in all cases
902-6 or 902-13 cells. for both kinesin and dynein. This distribution is consis-
Characteristics of cells harboring expanded polyQ tent with previous studies showing that 95% cellular
AR-Q56 constructs (902-6 and 902-13) were compared kinesin is membrane associated (Elluru et al., 1995; Tsai
to wtAR controls. After plating and growth in serum- et al., 2000). Similarly, the 74.1 antibody used to localize
containing medium, wtAR-transfected SH-SY5Y cells dynein preferentially stains membrane-associated dy-
spread out in all directions. Upon serum withdrawal and nein in immunofluorescence (Li et al., 2000). BDNF in-
BDNF addition, they developed polarized, elongated duction of differentiation increased kinesin levels mod-
morphologies (Figure 3A, left column). By 25 days in erately. Presence of AR-Q56 did not dramatically alter
culture (19 days postBDNF application), a network of distribution patterns for motors relative to wtAR cells,
neurites comparable to induced, untransfected SH- although slight increases in kinesin immunoreactivity
SY5Y cells (Encinas et al., 2000) was obvious. In con- were seen in the periphery of some 902-6-expressing
trast, 902-6 cultures appeared less differentiated at each cells. This distribution may result from the altered mor-
time point (Figure 3A, right column). Morphological dif- phology of these cells or differences in cell motility.
ferences were obvious even 3 days after BDNF treat-
ment, as shown by tubulin staining of fixed cultures Expanded PolyQ Forms of AR Inhibit Fast Axonal
(Figure 3B). Cell lengths were measured to quantitate Transport in Isolated Axoplasm
differences. Results of parametric statistical analysis As with N-terminal huntingtin polypeptides, perfusion
are shown in Table 1. Mean cell lengths for all three with subnanomolar concentrations of in vitro translated
lines differed significantly (p  0.01, Student’s t test), full-length or N-terminal wild-type AR had no detectable
with wtAR cells being longest and 902-6 cells shortest. effect on fast axonal transport in isolated axoplasm (Fig-
Histograms in Figure 3B show percentages of cells ures 5A, 5D, and 5F). In contrast, perfusion of compara-
within a given size range for each cell line. In wtAR, 30% ble amounts of full-length or N-terminal expanded polyQ
of analyzed cells are 61 m, while in 902-13 44% and AR inhibited both directions of transport significantly
in 902-6 66% of cells fell within this range. Conversely, (Figures 5B, 5E, and 5F). These effects were not asso-
40% of wtAR cells are 81 m, whereas only 15% of ciated with aggregate formation in expanded polyQ
902-13 and 8% of 902-6 cells are this long. Despite AR, because full-length AR with wild-type (20Q) and
significant differences in both mean values and shapes pathogenic (56Q) length polyglutamine tract behaved
of histograms, there was overlap in cell morphologies. comparably in gel filtration chromatography (Figure 5C).
Interestingly, double immunostaining of 902-6 cells for Perfusion with full-length pathogenic AR affected an-
AR and tubulin showed that cells with more differenti- terograde transport more severely than retrograde,
ated shapes had lower levels of polyQ-AR (Figure 3C, whereas effects of pathogenic AR N-terminal fragments
see Supplemental Figure S1 at http://www.neuron.org/ (Figure 5E) resembled huntingtin N-terminal polypeptide
cgi/content/full/40/1/41/DC1). effects. However, both full-length and N-terminal frag-
Changes in cell number after various treatments were ments significantly inhibited transport in both antero-
monitored over time to determine if growth rates in se-
grade and retrograde directions (p 0.0001). Fragments
rum-containing medium, growth arrest in response to
with expanded polyQ fragments affected both antero-
retinoic acid and BDNF, or cell death after growth factor
grade and retrograde transport more severely than full-
withdrawal differed between wt AR and 902-6 cells.
length cognates (Figures 5B, 5E, and 5F), consistent902-6 cells were selected because they had higher
with the more severe attenuation in neurite outgrowthpolyQ-AR immunoreactivity (Figure 2) and more severe
in 902-6 cells relative to 902-13 cells (Figure 3 and Tablemorphological defects (Figure 3B). Mean values in cell
1). This differential effect may reflect differences in con-numbers between cell lines (Figures 3D and 3E) showed
centration of polyQ-containing polypeptide. In vitrocomparable proliferation rates with serum (days 1–6),
translation methods typically produce more copies ofand both cell lines responded to BDNF in serum-free
shorter constructs, so N-terminal fragments may bemedium (day 6) by growth arrest (Figure 3D). Both wtAR
present at higher concentration. Consistent with this,and 902-6 cells exhibited significant loss of cells after
staining of 902-6 cells show increased levels of polyQBDNF removal (Figure 3E). Average cell numbers in
domains when truncated peptide is taken into account902-6 cultures were reduced relative to parallel wtAR
(see 1C2 and N20 staining in Figures 2F and 2H ascultures after growth factor washout in four independent
compared to 441 staining in Figure 2F).experiments, but differences did not reach significance
Consistent with observations that expanded polyQ AR(p  0.1 in Student’s t test). Taken together, these data
inhibits transport of neuronal organelles, mitochondrialindicate that expression of expanded polyQ AR attenu-
distribution was affected in a neuron-like cell line ex-ates outgrowth of neurites without affecting other as-
pressing high levels of an expanded polyQ mutant ARpects of cell behavior.
recombinant protein (Piccioni et al., 2002). However,Overall distribution of motor proteins is not altered in
transport defects do not result from inhibition of energypolyQ AR-expressing cells. A possible explanation for
production by oxidative phosphorylation because perfu-defective axonal transport in isolated axoplasm and
sion buffer contains 5 mM ATP, which supports trans-transport-dependent neurite extension in polyQ AR-
port in the absence of mitochondrial function (Brady etcontaining intact cells is that expansion of polyQ tracts
al., 1985). This suggests that effects of expanded polyQalters motor protein distribution. To evaluate distribu-
peptides on fast axonal transport are mediated throughtions of kinesin and dynein in intact cells, uninduced
an action on microtubule motor function rather than onSH-SY5Y cells with and without transfection (Figure 4A)
and BDNF-induced wtAR and 902-6 cells (Figure 4B) cellular energy supplies.
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Figure 3. PolyQ-AR Inhibits Process Elongation in SH-SY5Y Cells
(A) Phase images of live wtAR and 902-6 cells at various times after plating. Differentiation was induced with BDNF on day 6. WtAR cells
were more elongated than 902-6 cells at each time point and formed fasciculated networks of neuritic processes by 2 weeks.
(B) Cells immunostained for -tubulin (DM1A, Sigma) are shown 3 days after BDNF treatment. Histograms show cell length distributions. Even
at early times, most wtAR cells were elongated, whereas 902-6 cells were smaller and less polarized. 902-13 cells were intermediate in size
between wtAR and 902-6 cells. Thus, presence of the small N-terminal fragment correlates with more pronounced phenotypic differences.
(C) In a given 902-6 cell culture, subpopulations of cells with phenotypes like wtAR could occasionally be seen. Comparison of AR (N20) and
tubulin immunoreactivity indicates that more elongated, differentiated cells expressed much lower levels of polyQ-AR (arrow). Cells with
intense AR staining (*) lacked polarity, indicating that presence of expanded polyQ domain inhibits process extension.
(D) Effects of expanded polyQ domains on proliferation and survival were evaluated by counting live cells in wtAR and 902-6 cultures in the
corresponding areas of culture dishes defined by marks etched into coverslips. Results of a single experiment are shown. Error bars are SEM
with n 30 squares counted. Retinoic acid was added 1 day postplating and BDNF on day 6. Similar results were obtained in three independent
experiments involving 66 squares on 7 dishes for each cell line and by cell counts of trypsinized cells in three independent experiments with
a total of 8 plates for each time point (data not shown). There were no significant differences between cell lines in replication rates with serum-
containing medium or growth arrest in response to BDNF in serum-free medium.
(E) To test sensitivity of wtAR and 902-6 cells to withdrawal of trophic factors, cell numbers in cultures grown for 3 days in BDNF (BDNF)
were compared to cell numbers remaining 2–3 days after growth factor washout (	BDNF). Hemocytometer cell counts following trypsinization
are shown. Error bars are SEM with n  5 plates for BDNF for each cell line, and n  10 for 	BDNF. Qualitatively similar results were
obtained by counting live cells in the same dish before and after BDNF washout (not shown).
Discussion taining polyQ-tracts of lengths associated with neurode-
generative diseases compromise membrane trafficking
in fast axonal transport. Pathogenic forms of differentInhibition of fast axonal transport provides a novel
mechanism for polyQ pathogenesis. Polypeptides con- recombinant constructs for huntingtin and androgen re-
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Table 1. Expansion of Polyglutamine Tracts Affects Cell Morphology
Cell Line wtAR 902-6 902-13 wtAR 902-6 wtAR 902-6
Substrate Collagen Collagen Collagen p-D-lysine p-D-lysine Collagen Collagen
Measured Tubulin Tubulin Tubulin Tubulin Tubulin Cell-Track Cell-Track
Mean (SEM) 75 (4) 56 (2) 62 (2) 79 (3) 60 (2) 95 (4) 69 (2)
Minimum 39 32 24 32 30 37 38
Median 73 52 61 74 55 81 67
Maximum 138 100 135 179 112 215 194
Sample size 43 96 77 101 101 106 106
902-6 and 902-13 cells (56Q) have shorter processes than wtAR cells (Q20). Cell length was measured in microns in images of fixed cultures
stained with tubulin or Cell-Track. Cells were grown on either collagen I- or poly-D-lysine-coated slides. 902-6 cell lengths differed significantly
from wtAR cells (p  8E-09 for each sample pair, in Student’s t test). 902-13 cell lengths also differed significantly from both wtAR cells and
902-6 cells (p  1E-03 for each sample pair), showing that 902-13 has an intermediate morphological phenotype. Length measurements with
Cell-Track were significantly larger than with tubulin for all cases, but the cell length differences between poly-D-lysine and collagen I were
not different.
ceptor exhibited a characteristic inhibition of antero- formation is a complex, multistep event, inhibition of
either kinesin and dynein function is sufficient to inhibitgrade and retrograde transport distinct from effects
seen with a wide range of mutant and normal proteins neurite growth. Given that studies in isolated axoplasm
exhibit inhibition of both kinesin- and dynein-based vesi-introduced into isolated axoplasm (Pfister et al., 1989;
Ratner et al., 1998; Stenoien and Brady, 1997). This cle transport by proteins with expanded polyQ tracts,
attenuation of process formation by mutant AR polypep-suggests that expansion of polyQ sequences confers a
toxic gain of function consistent with dominant inheri- tides is consistent with inhibition of kinesin and dynein
function by these proteins.tance of polyQ diseases. Furthermore, toxic effects of
expanded polyQ segments did not require formation of Inhibition of fast axonal transport by pathogenic forms
of huntingtin and AR represents a toxic gain of functionmorphologically detectable aggregates.
Characteristic features of polyQ expansion diseases consistent with dominant inheritance patterns for HD
and SBMA. The large size and distinctive subcellularshould be explained by any candidate pathogenic mech-
anism. These include toxic gain of function, threshold organization of neurons makes them uniquely depen-
dent on fast axonal transport to provide membrane pro-polyQ length, preferential loss of neurons, and delayed
disease onset (Gusella and MacDonald, 2000; Orr, 2001; teins and organelles. Virtually all protein synthesis oc-
curs in perikarya, and materials must be deliveredZoghbi and Orr, 2000). Pathological activities gained by
expanding polyQ tracts need not be related to normal efficiently to axonal regions that may comprise99.9%
of membranes in a neuron (Brady, 1993). Neurons arefunctions of the various unrelated proteins associated
with polyQ neurodegenerative disorders (Fischbeck, affected earlier and more severely than other cell types
by toxic treatments that compromise fast axonal trans-2001).
Axoplasm experiments indicate that polypeptides port, such as vincristine and acrylamide (Sahenk et al.,
1986; Sickles et al., 1996).containing expanded polyQ tracts in cytoplasm are suffi-
cient to affect transport, because isolated axoplasm Recent reports indicate that inhibition of one or more
microtubule-based motors can lead to neurodegenera-contains neither nuclei nor protein synthesis. Inhibition
of fast axonal transport by peptides containing ex- tion. For example, a form of autosomal dominant heredi-
tary spastic paraplegia results from loss of function mu-panded polyQ tracts occurs at concentrations two or-
ders of magnitude lower than concentrations of motor tation in the motor domain of a neuron-specific kinesin.
Patients with these mutations exhibit axonal degenera-proteins responsible for transport. Consistent with ob-
servations of increased toxicity for truncated polyglu- tion in the longest CNS axons with age of onset between
11 and 30 years of age (Reid et al., 2002). Mutationstamine proteins (Hackam et al., 1998; Merry et al., 1998;
Orr, 2001; Wellington et al., 1998), truncated polypep- in another kinesin family member are responsible for
Charcot-Marie-Tooth Type 2A peripheral neuropathytides containing expanded polyQ sequences affect
transport more severely than full-length proteins, and (Zhao et al., 2001), indicating that insufficient transport
of vesicle proteins can produce degeneration in a subsethigher levels of cytoplasmic expanded polyQ tract may
be more toxic. These results suggest that proteins with of neurons. Mutations in dynein also produce motor
neuron degeneration (Hafezparast et al., 2003).polyQ expansion affect cellular activities dependent on
kinesin and dynein, specifically fast axonal transport. The late onset of disease typical of polyQ disorders
suggests a chronic rather than acute pathogenic pro-A variety of experiments indicate that neurite out-
growth is dependent on microtubule-based motor pro- cess. Many cellular activities gradually decline during
aging, and axonal transport in neurons is no exception.teins. Inhibition of kinesin function with specific antibod-
ies or reduction of kinesin levels with antisense RNA In particular, rates and amounts of material in axonal
transport decline with aging (Goemaere-Vanneste et al.,(Amaratunga et al., 1993; Feiguin et al., 1994) inhibits
process formation in neurons, indicating a role for 1988; McQuarrie et al., 1989), and these changes corre-
late with reduced neuronal plasticity and regenerationkinesin-dependent transport. Similarly, disruption of
dynein function inhibits process formation (Ferhat et (Pestronk et al., 1980; Schwab, 1996). Although not ex-
amined here, slow axonal transport of the cytoskeletonal., 2001; Hafezparast et al., 2003). Although process
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may also involve kinesins or dynein (Brady, 2000), and
inhibition of slow transport could further compromise
affected neurons. Presence of pathogenic polyQ poly-
peptides may compromise fast axonal transport in af-
fected neurons by reducing transport below normal lev-
els for a given age and neuron. When amounts of
essential materials delivered by fast transport fall below
minimum levels needed, affected neurons begin to die.
Thus, inhibition of fast axonal transport by polypeptides
containing expanded polyQ segments provides an ex-
planation consistent with a toxic gain of function, prefer-
ential loss of neurons, and late disease onset.
Loss of specific neuronal populations is not explicitly
addressed by these experiments. However, huntingtin
and AR levels vary among neuronal populations, and
the specific protein context may determine selective
vulnerability of specific neuronal populations (Gusella
and MacDonald, 2000; Orr, 2001; Zoghbi and Orr, 2000).
Inhibition of transport by subnanomolar concentrations
of polypeptides with expanded polyQ tracts suggests an
effect on enzymatic activities that modulate fast axonal
transport (Morfini et al., 2002; Ratner et al., 1998; Tsai
et al., 2000) rather than a direct effect on motor proteins.
Cell-specific differences in these essential pathways
may lead to lower thresholds for some neuronal popula-
tions than others. For example, limiting levels of neuro-
trophins supplied by neuronal targets may increase vul-
nerability in a given neuronal population, or there may
be differences in ratios of pathogenic polypeptide to
neuronal target proteins. Similar arguments were in-
voked to explain why the largest and/or longest neurons
are particularly vulnerable in toxic neuropathies and
models of amyotrophic lateral sclerosis (Brady, 1995).
Kinesin- and dynein-based motility of membrane
bounded organelles is highly conserved across species.
Inhibition of fast axonal transport in isolated axoplasm
and of neurite extension in mammalian neuronal cell
lines by polypeptides containing pathogenic polyglu-
tamine expansions are consistent with a common mech-
anism. Ideally, these studies will be extended to trans-
genic mouse models for glutamine expansion diseases.
However, misexpression of proteins, particularly over-
expression, may produce pathologies distinct from the
polyglutamine expansion pathway (i.e., see Szebenyi
et al., 2002). Late onset for neuronal degeneration in
polyglutamine expansion diseases suggests that trans-
port defects may be subtle prior to onset of symptoms,
particularly in neurons slow to exhibit pathology. Based
on observations presented here, we expect the amount
of kinesin- and/or dynein-transported cargos in the ter-
minals to be affected and average transport rates to beFigure 4. Distributions of Kinesin and Dynein in wtAR and 902-6
reduced but not eliminated. Fast axonal transport ratesCells
and amounts are not easily measured in the cortical(A) Immunostaining with kinesin antibodies H2 and 63-90 (kinesin)
neurons most severely affected in Huntington’s diseaseand anti-dynein intermediate chain antibody 74.1 (dynein) in non-
and SBMA, but a detailed analysis in appropriate neu-transfected cells (wt), cells stably transfected with wild-type AR
(wtAR), or cells transfected with mutant AR (902-6 and 902-13) in ronal systems should reveal decrements in transport.
uninduced cells grown in serum. Localization of kinesin and dynein Precedent for this is found in demonstrations that muta-
were similar in all cell lines. tions in presenilin 1 associated with familial forms of
(B) Immunostaining with kinesin and dynein antibodies in wtAR and Alzheimer’s disease increase levels of active glycogen902-6 cells induced by BDNF. H2 staining patterns in induced 902-6
synthase kinase 3 and reduce kinesin-based motility incells often appeared patchy with accumulations at the periphery,
neurons by 20%–30% (Pigino et al., 2003).but such patterns were not seen in wtAR. Similarly, no consistent
Although polyglutamine expansion diseases sharechanges were detected in dynein distribution in 902-6 cells as com-
pared to wtAR cells, although comparisons are difficult due to differ- many features, there are also indications that disease-
ent cell morphologies of induced wtAR and 902-6 cells. specific elements that may be related to protein context
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Figure 5. Full-Length and N-Terminal Fragments of Androgen Receptor with Pathogenic PolyQ Domains Inhibit Fast Axonal Transport in
Isolated Axoplasm
Full-length or N-terminal fragments of androgen receptor containing wild-type (AR Q20) or pathogenic polyQ (AR-Q56) domains were synthe-
sized by in vitro translation.
(A and B) Full-length AR-Q20 (A) had no effect on transport of organelles in either direction, but AR-Q56 (B) inhibited both directions significantly
(p  0.0001, pooled t test). The effect of full-length AR-Q56 was more pronounced on anterograde.
(C) Pathogenic and wild-type androgen receptors used in axoplasm experiments behaved indistinguishably in gel filtration chromatography.
Neither had detectable levels of aggregated AR, indicating that aggregates were not required for effects on transport.
(D and E) N-terminal truncated AR containing wild-type (AR-Q20 fragment) or pathogenic polyQ (AR-Q56 fragment) tracts were used to
determine whether polyQ-containing fragments differed from full-length AR. As with full-length AR, AR-Q20 fragments (D) had no discernible
effect on transport, but pathogenic AR-Q56 fragments (E) inhibited both directions of transport.
(F) Histograms comparing actions of normal and pathogenic AR polypeptides on fast axonal transport after 25–35 min of observation. Fast
axonal transport with nonpathogenic full-length and N-terminal fragment polypeptides was indistinguishable from vector controls (data not
shown). In contrast, pathogenic full-length and N-terminal fragments inhibited fast axonal transport in both directions significantly (#p 
0.0001 in a pooled t test) relative to corresponding nonpathogenic constructs. Pathogenic N-terminal AR-Q56 fragments inhibited transport
to a greater extent than full-length AR-Q56 (*p  0.0005 and **p  0.0001, pooled t test). As in transfected SH-SY5Y cells, truncated forms
of proteins with pathogenic polyQ domains appear more toxic.
or physiological function of polypeptides containing week-old mice), but neuropathology may occur in the
absence of hormone with a longer time course. Consis-polyglutamine expansions (Gusella and MacDonald,
2000; Orr, 2001). For example, recent reports find that tent with this, many patients with SBMA exhibit signs
and symptoms indicative of mild androgen insensitivityhormonal ligand may play an important role in SBMA
(Katsuno et al., 2002; Takeyama et al., 2002). These (Wieacker et al., 1998), indicating that the expanded
repeat AR is not fully competent as a transcription factor.studies report that increased hormone levels lead to
loss of neurons in mice and Drosophila models, presum- In this context, increasing mutant protein concentration
in cell bodies by hormone treatment may enhance toxic-ably by increasing nuclear levels of mutant protein. Kat-
suno et al. (2002) suggest that hormone is required for ity by interfering with transport in the perikarya or by
expressing a second cytotoxic effect in the nucleus orneuropathology, but this conclusion must be tempered
by other observations. For example, Takeyama et al. both. Regardless, our observations demonstrate that
two unrelated sets of polypeptides with polyQ expan-(2002) note that presence of a truncated form of the AR
induces similar pathology without hormone, consistent sions inhibit fast axonal transport.
Effects of N-terminal huntingtin and AR with expandedwith our observation that a truncated AR peptide has a
more profound effect on axonal transport than full- polyQ tracts on fast axonal transport suggest that decre-
ments in axonal transport are a component of pathogen-length receptor. Others have reported that testosterone
treatment increases cell viability in cellular models of esis in HD, SBMA, and probably other polyQ expansion
diseases. Other neuronal functions may also be compro-SBMA (Piccioni et al., 2001). Katsuno et al. (2002) also
restricted analysis to relatively young animals (30- mised in these diseases as a consequence of polyQ
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cance was evaluated by Student’s or pooled t test of 1-2 usingexpansion. For example, formation of aggregates and
DataDesk 5.0 (Data Description, Ithaca, NY).nuclear localization might exacerbate or contribute to
neuropathology in these diseases. However, compro-
SH-SY5Y Cell Culturemised fast axonal transport is likely to be a primary
Androgen receptor (AR) constructs containing wild-type Q20 and
lesion leading to neuronal degeneration, and fast axonal pathogenic (SBMA) Q56 tracts were prepared and stably transfected
transport represents a promising target for designing into SH-SY5Y human neuroblastoma cells (unpublished results).
and testing treatments to slow or block neurodegener- Stably transfected clones of SH-SY5Y cells (wtAR, 902-6, and 902-
13) as well as nontransfected cells were grown and differentiatedation.
according to Encinas et al. (2000), with some modifications. Two
stably transfected mutant cell lines were selected because theyExperimental Procedures
expressed comparable levels of full-length androgen receptor, and
902-6 cells expressed a truncated N-terminal fragment of the andro-Recombinant Huntingtin and Androgen
gen receptor that accumulated in the cytoplasm. Briefly, cells wereReceptor Polypeptides
plated on poly-D-lysine or collagen surfaces in growth mediumExpression vectors encoding amino acids 1–548 of human hunting-
(DMEM/F12 medium [GIBCO] supplemented with 10% fetal bovinetin protein engineered to contain either an N-terminal FLAG epitope
serum [Hyclone], 2 mM L-glutamine, and a cocktail of antibioticstag or a C-terminal GFP tag were constructed in pCDNA3 (Invitrogen)
[Cellgro]). For immunocytochemistry and morphometric studies,as described previously (Faber et al., 1998). Plasmids containing
cells were plated at densities of 3000–5000 cells/cm2 on 4-well tis-full-length or sauI amino-terminal fragment androgen receptor con-
sue-tech chamber slides (Becton-Dickinson) and for biochemicalstructs were similarly prepared. Polypeptides for these assays were
studies at 10,000 cells/cm2 on 10 cm tissue culture dishes. Undiffer-produced by in vitro transcription/translation (Promega; TnT T7 cou-
entiated cells were maintained in growth medium. To induce neu-pled Reticulocyte Lysate system) according to manufacturer’s pro-
ronal differentiation, 10 mM retinoic acid was added in growth me-tocols. Typically, 1 g of plasmid was transcribed in 50 l reaction
dium, typically within 48 hr of cell plating. After 5–7 days of retinoicmix. To assess protein levels, parallel transcription/translation reac-
acid treatment, cells were washed 3 times with serum-free DMEM/tions were performed incorporating 35S-labeled methionine (Amer-
F12 and incubated in differentiating medium (DMEM/F12 supple-sham) or by quantitative immunoblots. Concentrations were typi-
mented with 50 ng/ml BDNF [Alomone], 2 mM L-glutamine, andcally between 0.2 and 0.5 nM protein. Generally, higher numbers of
antibiotics). Cells were maintained in differentiating medium for upglutamines resulted in slightly lower concentrations of translated
to 30 days, with 50% of medium changed every 3–4 days.protein under identical conditions. In vitro translation products were
briefly centrifuged to eliminate translation machinery and superna-
Cell Fractionation and Western Blottingtants frozen in liquid N2 until used.
Cells were rinsed with PHEM (60 mM PIPES, 25 mM HEPES, 10 mMIn some experiments, androgen receptor translation mixtures
EGTA, 1 mM MgCl2 [pH 7.4]) at 37
C, scraped into Homogenizationwere fractionated on Sephacryl S-300 HR. Immunoreactive AR
buffer (10 mM HEPES [pH 7.4] and 2 mM EDTA), and homogenized(above) was detected in immunoblots using antibody directed at
with 20 strokes in a Dounce homogenizer. After 20 min incubation,the N terminus of AR (U402). Relative levels of immunoreactive AR
sucrose was added to a final concentration of 250 mM. Crude nu-in different column fractions were plotted and compared to elution
clear pellet was obtained by centrifugation at 2000  g for 5 min.patterns of molecular size markers (BD: blue dextran dye, 2  106
Supernatants were further centrifuged at 12,500  g for 8 min tokD; TG: thyroglobulin, 6.69 105 kD; Am: amylase, 2 105 kD; BSA:
obtain a mitochondrial fraction, and that supernatant was centri-bovine serum albumin, 6.6  104 kD).
fuged at 150,000  g for 40 min in a TLA 100.3 rotor to obtain
microsomal pellet and cytosolic supernatant fractions. To solubilizeFast Axonal Transport in Isolated Axoplasm
samples, SDS was added to 0.1%.Axoplasm was extruded from giant axons of squid (Loligo pealii;
Protein concentrations were determined by Coomassie Plus Pro-Marine Biological Laboratory, Woods Hole, MA) as described pre-
tein Assay (Pierce, Rockford, IL). All samples were brought to theviously (Brady et al., 1985). Briefly, 2–2.5 cm of axon was dissected
same concentration in homogenization buffer and sample bufferand 4–5 l of axoplasm extruded onto a 0 thickness coverslip as a
(0.35 M Tris-HCl [pH 6.8], 10.3% SDS [Pierce], 36% glycerol, 5%well-organized cytoplasmic cylinder with known polarity. Axoplasm
-mercaptoethanol, 0.01% bromphenol blue), and equal amountsis sandwiched between two coverslips with 150 m thick spacers
of protein from each sample were loaded to lanes of a 4%–15%to form an incubation chamber of 25l for perfusion with physiologi-
SDS-PAGE gel. Some gels were Coomassie blue stained to furthercal buffers containing polypeptides of interest. Absence of perme-
assure similar protein concentrations in all the samples. Proteinsability barriers allows introduction of impermeant compounds like
were transferred to nitrocellulose (Schleicher & Schuell) for 1 hr atnucleotide analogs (Lasek and Brady, 1985), antibodies (Stenoien
100 V in Tris-glycine buffer. Transfer of proteins was assessed byand Brady, 1997), and recombinant proteins (Ratner et al., 1998)
Ponceau (Sigma) staining. Membranes were blocked by incubationinto axoplasm at defined concentrations. Proteins for perfusion into
in 5% non-fat dry milk in PBS [pH 7.4] for 1 hr at 4
C. Antibodiesaxoplasm were diluted 1:1 with buffer X (350 mM potassium aspar-
were incubated with membranes in blocking buffer overnight at 4
C.tate, 130 mM taurine, 70 mM betaine, 50 mM glycine, 20 mM HEPES,
Washes after incubations were in 0.25% Tween-20 in PBS at room13 mM MgCl2, 10 mM EGTA, 3 mM CaCl2, 1 mM glucose [pH 7.2],
temperature and were repeated 5 times, for a total length of aboutsupplemented with 10 mM ATP), which is modeled after the small
30 min. Blots were then incubated with secondary antibodies formolecular weight composition of axoplasm (Brady et al., 1985). Fast
1 hr at 4
C, then washed as above, except last washes were withoutaxonal transport in isolated axoplasm continues for 2 hr in buffer
detergent. Finally, blots were developed in an ECL chemilumines-X or half-strength buffer X (X/2) (Stenoien and Brady, 1997). Recom-
cent assay (Amersham Biosciences) and exposed to Blue Biofilmbinant polypeptides were thawed just prior to use and analyzed
(Denville Scientific) for 30 s–30 min. For quantitation, immunoblotswithin 24 hr of thawing. Recombinant polypeptide in X/2 (20 l) is
were done under identical conditions and AR immunoreactivity visu-perfused into the chamber. Small molecular weight components like
alized by chemiluminescence. Exposures were adjusted to assureATP or amino acids equilibrate between axoplasm and buffer within
that no band was saturated in scanned films. Band density was2–3 min, whereas polypeptides of the size employed here equilibrate
quantified with ImageJ software (NIH) and pixel values normalizedin 10–20 min (Brady et al., 1985).
to a loading control.Fast transport was evaluated by video enhanced contrast, differ-
ential interference contrast microscopy using a 100, 1.3NA plana-
pochromatic objective on a Zeiss Axiomat (Carl Zeiss, Inc., Immunofluorescence
Cells were rinsed with PHEM at 37
C, fixed in 2% paraformaldehydeThornwood, NY) interfaced with a Hamamatsu Argus 20 image pro-
cessor. Velocities are measured in real time using a Hamamatsu (Fisher)/0.01% glutaraldehyde (Electron Microscopy Sciences) in
PHEM for 10 min at 37
C, and rinsed several times in cold PBS (pHC2117 Videomanipulator. Data was plotted and curves fitted using
Deltagraph software (DeltaPoint, Monterrey, CA). Statistical signifi- 7.4) or fixed in cold methanol for 10 min. Aldehyde-fixed cells were
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permeabilized in 0.2% triton X-100 in PBS for 10 min at room temper- Block-Galarza, J., Chase, K.O., Sapp, E., Vaughn, K.T., Vallee, R.B.,
ature. Nonspecific binding was blocked by incubation in 2.5% gela- DiFiglia, M., and Aronin, N. (1997). Fast transport and retrograde
tin/3% BSA/0.2% Tween 20 in PBS (pH 7.4) for 1 hr. Antibodies movement of huntingtin and HAP 1 in axons. Neuroreport 8, 2247–
were diluted in blocking solution and incubated on slides overnight 2251.
at 4
C. Kinesin was detected with H2 and 63–90 antibodies; dynein Brady, S.T. (1993). Axonal dynamics and regeneration. In Neurore-
with anti 74.1 (Pfister et al., 1996); tubulin with DM1A (Sigma); andro- generation, A. Gorio, ed. (New York: Raven Press), pp. 7–36.
gen receptor with N20 (Santa Cruz), 447 (Santa Cruz), U402, and
Brady, S.T. (1995). Motor neuron diseases: interfering with the run-U407 (McPhaul); and polyglutamine with 1C2 (Chemicon). Washes
ners. Nature 375, 12–13.were in 0.2% Tween-20 in PBS. Goat anti-mouse and anti-rabbit
Brady, S.T. (2000). Neurofilaments run sprints not marathons. Nat.secondary antibodies, labeled with Texas red, Alexa 488, or Alexa
Cell Biol. 2, E43–E45.594 (Molecular Probes), were applied at room temperature for 1 hr
and slides washed as above. To stain nuclei, slides were dipped Brady, S.T., Lasek, R.J., and Allen, R.D. (1985). Video microscopy
into 0.5 g/ml Hoechst solution (Aldrich Chemicals, St. Louis, MO) of fast axonal transport in isolated axoplasm: a new model for study
for 2–10 min. After rinses in 50 mM Tris (pH 8.0), sections were of molecular mechanisms. Cell Motil. 5, 81–101.
coverslipped with Gel/Mount (Biomedia, Foster City, CA). Brady, S.T., Pfister, K.K., and Bloom, G.S. (1990). A monoclonal
Axoplasms were extruded onto coverslips and incubated with 5l antibody against kinesin inhibits both anterograde and retrograde
of HD548 Q23flag, or HD548 Q62flag in X/2 to minimize dilution or fast axonal transport in squid axoplasm. Proc. Natl. Acad. Sci. USA
extraction. Samples were incubated for 30 min at room temperature, 87, 1061–1065.
and then 15 l of HBS (50 mM HEPES [pH 7.2], 150 mM NaCl) 
Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor,2% bovine serum albumin (BSA) was added to minimize nonspecific
M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas,interactions. Excess buffer was wicked off and the process re-
J., and Zoghbi, H.Y. (2003). Interaction of akt-phosphorylatedpeated. Axoplasms were then fixed by immersion either in 95%
ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellarethanol/5% acetic acid at 	20
C for 10 min or in 50 l freshly
ataxia type 1. Cell 113, 457–468.prepared 3.7% paraformaldehyde in HBS at room temperature for
30 min, replacing formaldehyde fix 3–4 times during fixation. After DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young,
fixation, axoplasms were rinsed once in 50 l HBS and once in 50 C., Martin, E., Vonsattel, J.P., Carraway, R., Reeves, S.A., et al.
l HBS  2% BSA at room temperature for 10 min each wash. (1995). Huntingtin is a cytoplasmic protein associated with vesicles
Axoplasms were incubated for 1 hr at room temperature in 50 l in human and rat brain neurons. Neuron 14, 1075–1081.
anti-FLAG antibody (M2 or M5 monoclonal antibodies, Eastman Elluru, R., Bloom, G.S., and Brady, S.T. (1995). Fast axonal transport
Kodak) made up at 20 g/ml in HBS  10% BSA. Samples were of kinesin in the rat visual system: functionality of the kinesin heavy
washed 3 times as above in HBS  2% BSA, then incubated with chain isoforms. Mol. Biol. Cell 6, 21–40.
TRITC-goat antimouse IgG (Jackson ImmunoResearch) at 30 g/ml
Emamian, E.S., Kaytor, M.D., Duvick, L.A., Zu, T., Tousey, S.K.,in HBS  10% BSA for 1 hr at room temperature. Finally, samples
Zoghbi, H.Y., Clark, H.B., and Orr, H.T. (2003). Serine 776 of ataxin-1were washed 3 times again in HBS 2% BSA. Slides were mounted
is critical for polyglutamine-induced disease in SCA1 transgenicwith Slow Fade Light (Molecular Probes) and sealed. Images were
mice. Neuron 38, 375–387.obtained using a Zeiss LSM 410 Laser Scanning Confocal Micro-
scope. All images were acquired with identical settings and the Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Cena, V.,
panel assembled in Photoshop before adjusting contrast on both Gallego, C., and Comella, J.X. (2000). Sequential treatment of SH-
panels at the same time. SY5Y cells with retinoic acid and brain-derived neurotrophic factor
gives rise to fully differentiated, neurotrophic factor-dependent, hu-
Cell Imaging and Morphometry man neuron-like cells. J. Neurochem. 75, 991–1003.
Stained preparations were viewed with epifluorescent illumination Faber, P.W., Barnes, G.T., Srinidhi, J., Chen, J., Gusella, J.F., and
using AttoArc on a Zeiss Axiovert 100M microscope (Thornwood, MacDonald, M.E. (1998). Huntingtin interacts with a family of WW
NY). Objectives used included 40 F Fluar (NA 1.3) and 100 (NA domain proteins. Hum. Mol. Genet. 7, 1463–1474.
1.4) Plan Apochromat. Images were obtained with an Orca CCD
Feiguin, F., Ferreira, A., Kosik, K.S., and Caceres, A. (1994). Kinesin-camera (Hamamatsu, Japan) controlled by Openlab (Improvision,
mediated organelle translocation revealed by specific cellular ma-Boston, MA) and prepared for presentation in Photoshop (Adobe
nipulations. J. Cell Biol. 127, 1021–1039.Systems, Mountain View, CA). Images within a panel were adjusted
together for contrast. Live cells were imaged by phase optics and Ferhat, L., Rami, G., Medina, I., Ben-Ari, Y., and Represa, A. (2001).
images acquired on the same imaging platform. Morphometric mea- Process formation results from the imbalance between motor-medi-
surements were done in Openlab. Statistical significance for differ- ated forces. J. Cell Sci. 114, 3899–3904.
ences in cell number and lengths were evaluated by Student’s t test Fischbeck, K.H. (2001). Polyglutamine expansion neurodegenera-
in Microsoft Excel and in Deltagraph and additional statistical tests tive disease. Brain Res. Bull. 56, 161–163.
with DataDesk software.
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